Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vanda Pharmaceuticals Inc.

     Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vanda
                             Pharmaceuticals Inc.

PR Newswire

NEW YORK, June 19, 2013

NEW YORK, June 19, 2013 /PRNewswire/ --Attorney Advertising -- Bronstein,
Gewirtz & Grossman, LLC is investigating potential claims on behalf of
purchasers of the securities of Vanda Pharmaceuticals, Inc.("Vanda" or the
"Company") (NasdaqGM: VNDA). The investigation focuses on whether the Company
and its executives violated federal securities laws.

On June 19, 2013, shares of Vanda fell $2.42 or 22% to trade at $8.50 during
intraday trading after an article on appeared on the street.com alleging that
the design of Vanda's primary phase III study changed numerous times,
including a complete replacement of the primary endpoint just one month before
study results were announced. The replacement primary endpoint installed to
evaluate tasimelteon's benefit was created by Vanda and has never been used
before in sleep-drug clinical trials, nor was it endorsed by the FDA. The
street.com also alleged that during the tasimelteon clinical trials, Vanda cut
half the patient enrollment because the blind patients with non-24 could not
be identified. In May, Vanda submitted a U.S. approval application for
tasimelteon to treat non-24 disorder. The U.S. Food and Drug Administration
has not yet accepted the tasimelteon submission for review or set an official
approval decision date.

If you are aware of any facts relating to this investigation, or purchased
shares of Vanda Pharmaceuticals you can assist this investigation by
contacting either Peretz Bronstein or his Investor Relations Coordinator Eitan
Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
eitan@bgandg.com. Those who inquire by e-mail are encouraged to include their
mailing address and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar
outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com



SOURCE Bronstein, Gewirtz & Grossman, LLC

Website: http://www.bgandg.com